TriSalus Life Sciences (TLSI) Stock Overview
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
TLSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeTriSalus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.46 |
| 52 Week High | US$7.95 |
| 52 Week Low | US$3.42 |
| Beta | 0.56 |
| 1 Month Change | 12.63% |
| 3 Month Change | -6.11% |
| 1 Year Change | -14.07% |
| 3 Year Change | -56.78% |
| 5 Year Change | -53.88% |
| Change since IPO | -57.60% |
Recent News & Updates
Recent updates
Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops and commercializes pressure enabled drug delivery technologies and catheters used in interventional procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
Summary TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025. Despite risks like low cash reserves and potential dilution, I maintain a "buy" rating, contingent on continued sales growth and stable financial reporting. Read the full article on Seeking AlphaTriSalus Life Sciences: Falling Despite Moving Forward Into The Market
Summary TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term. Read the full article on Seeking AlphaShareholder Returns
| TLSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | 1.2% | 2.1% |
| 1Y | -14.1% | 41.9% | 30.6% |
Return vs Industry: TLSI underperformed the US Biotechs industry which returned 41.9% over the past year.
Return vs Market: TLSI underperformed the US Market which returned 31% over the past year.
Price Volatility
| TLSI volatility | |
|---|---|
| TLSI Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TLSI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TLSI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 102 | Mary Szela | trisaluslifesci.com |
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
TriSalus Life Sciences, Inc. Fundamentals Summary
| TLSI fundamental statistics | |
|---|---|
| Market cap | US$279.44m |
| Earnings (TTM) | -US$69.69m |
| Revenue (TTM) | US$45.15m |
Is TLSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLSI income statement (TTM) | |
|---|---|
| Revenue | US$45.15m |
| Cost of Revenue | US$6.97m |
| Gross Profit | US$38.19m |
| Other Expenses | US$107.88m |
| Earnings | -US$69.69m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 12, 2026
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 84.57% |
| Net Profit Margin | -154.35% |
| Debt/Equity Ratio | -97.6% |
How did TLSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 19:22 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TriSalus Life Sciences, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Justin Walsh | JonesTrading Institutional Services, LLC |
| Frank Takkinen | Lake Street Capital Markets, LLC |